Amyris Inc  

(Public, NASDAQ:AMRS)   Watch this stock  
Find more results for NYSEARCA:amrs
-0.003 (-0.65%)
Mar 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.46 - 0.50
52 week 0.31 - 1.43
Open 0.47
Vol / Avg. 1.31M/2.76M
Mkt cap 134.26M
P/E     -
Div/yield     -
EPS -0.36
Shares 253.36M
Beta 0.70
Inst. own 37%
Mar 7, 2017
Q4 2016 Amyris Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -120.21% -113.14%
Operating margin -86.11% -116.68%
EBITD margin - -101.85%
Return on average assets -129.92% -71.01%
Return on average equity - -
Employees 418 -
CDP Score - -


5885 Hollis St Ste 100
EMERYVILLE, CA 94608-2405
United States - Map
+1-510-4500761 (Phone)
+1-510-2252645 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene). The Company is expanding its range of products across various categories divided into consumer and industrial applications. For consumer applications, the Company is developing and selling personal care products (which include ingredients for cosmetics and F&F), healthcare products and formulated end user products, such as Biossance brand skincare products and Muck Daddy brand hand cleaner product.

Officers and directors

John G. Melo President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Kathleen Valiasek Chief Financial Officer
Bio & Compensation  - Reuters
Joel Cherry Ph.D. President - Research and Development
Age: 54
Bio & Compensation  - Reuters
Karen D. Rohde Chief Human Resources Officer
Bio & Compensation  - Reuters
Chris Jaenike Interim General Counsel
Bio & Compensation  - Reuters
Abraham Klaeijsen Director
Bio & Compensation  - Reuters
Christophe Vuillez Director
Bio & Compensation  - Reuters
Patrick Y. Yang Director
Bio & Compensation  - Reuters
Abdullah Bin Khalifa Al Thani Independent Director
Age: 55
Bio & Compensation  - Reuters
John L. Doerr Independent Director
Age: 63
Bio & Compensation  - Reuters